In a filing, Cytokinetics Inc revealed its EVP, Chief Commercial Officer Callos Andrew unloaded Company’s shares for reported $68730.0 on Dec 08 ’25. In the deal valued at $65.96 per share,1,042 shares were sold. As a result of this transaction, Callos Andrew now holds 50,660 shares worth roughly $3.12 million.
Then, Callos Andrew sold 52,486 shares, generating $3,461,452 in total proceeds. Upon selling the shares at $65.95, the EVP, Chief Commercial Officer now owns 50,660 shares.
Before that, ANDREW CALLOS bought 53,528 shares. Cytokinetics Inc shares valued at $3,561,753 were divested by the Officer at a price of $66.54 per share.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -3.95% to $61.6. Over the last five days, the stock has lost -3.01%. Cytokinetics Inc shares have risen nearly 22.22% since the year began. Nevertheless, the stocks have risen 30.95% over the past one year. While a 52-week high of $69.33 was reached on 11/28/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 60.12, which if violated will result in even more drops to 58.64. On the upside, there is a resistance level at 64.27. A further resistance level may holdings at 66.93.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-11-14, growing by 0.18 million shares to a total of 14.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 14.2 million shares. There was a rise of 1.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
